The ubiquitin-proteasome system in cardiac physiology and pathology

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 1, 2006, Pages

  Powell, Saul R ^a,b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

Heart; Protein degradation

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CURCUMIN; EPOXIMICIN; GLIOTOXIN; POLYPHENOL DERIVATIVE; PR 39; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

APOPTOSIS; CARDIOMYOPATHY; CELL CYCLE; CELL LOSS; CELL SIZE; CONGESTIVE HEART FAILURE; DRUG MECHANISM; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNE RESPONSE; MYOFILAMENT; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; UBIQUITINATION;

ANIMALS; APOPTOSIS; HEART; HEART DISEASES; HUMANS; MODELS, CARDIOVASCULAR; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; UBIQUITIN;

EID: 33745726659     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00062.2006     Document Type: Review

References (238)

1. + channel (H1) by the ubiquitin-protein ligase Nedd4. FEBS Lett 466: 377-380, 2000.
2. Abriel H and Kass RS. Regulation of the voltage-gated cardiac sodium channel Nav1.5 by interacting proteins. Trends Cardiovasc Med 15: 35-40, 2005.
3. Adrain C, Creagh EM, Cullen SP, and Martin SJ. Caspase-dependent inactivation of proteasome function during programmed cell death in Drosophila and man. J Biol Chem 279: 36923-36930, 2004.
4. Amerik AY and Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 1695: 189-207, 2004.
5. Amici M, Lupidi G, Angeletti M, Fioretti E, and Eleuteri AM. Peroxynitrite-induced oxidation and its effects on isolated proteasomal systems. Free Radic Biol Med 34: 987-996, 2003.
6. Aravind L and Koonin EV. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 10: R132-R134, 2000.
7. Arden KC and Biggs WH III. Regulation of the FoxO family of transcription factors by phosphatidylinositol-3 kinase-activated signaling. Arch Biochem Biophys 403: 292-298, 2002.
8. Arrigo AP, Tanaka K, Goldberg AL, and Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 331: 192-194, 1988.
9. Arya R, Kedar V, Hwang JR, McDonough H, Li HH, Taylor J, and Patterson C. Muscle ring finger protein-1 inhibits PKCε activation and prevents cardiomyocyte hypertrophy. J Cell Biol 167: 1147-1159, 2004.
10. Asai A, Tanahashi N, Qiu JH, Saito N, Chi S, Kawahara N, Tanaka K, and Kirino T. Selective proteasomal dysfunction in the hippocampal CA1 region after transient forebrain ischemia. J Cereb Blood Flow Metab 22: 705-710, 2002.
11. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY, and Patterson C. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 19: 4535-4545, 1999.
12. Bao J, Sato K, Li M, Gao Y, Abid R, Aird W, Simons M, and Post MJ. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated IκBα degradation. Am J Physiol Heart Circ Physiol 281: H2612-H2618, 2001.
13. Baracos VE, De VC, Hoyle DH, and Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol Endocrinol Metab 268: E996-E1006, 1995.
14. Baumeister W, Walz J, Zuhl F, and Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92: 367-380, 1998.
15. Bence NF, Sampat RM, and Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292: 1552-1555, 2001.
16. Bergmann MW, Loser P, Dietz R, and Harsdorf R. Effect of NF-κB inhibition on TNF-α-induced apoptosis and downstream pathways in cardiomyocytes. J Mol Cell Cardiol 33: 1223-1232, 2001.
17. Bloom J, Amador V, Bartolini F, DeMartino G, and Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation. Cell 115: 71-82, 2003.
18. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, and Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704-1708, 2001.
19. Brodsky JL and McCracken AA. ER protein quality control and proteasome-mediated protein degradation. Semin Cell Dev Biol 10: 507-513, 1999.
20. Brunk UT and Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med 33: 611-619, 2002.
21. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, and Szweda LI. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057-30063, 2001.
22. Bulteau AL, Szweda LI, and Friguet B. Age-dependent declines in proteasome activity in the heart. Arch Biochem Biophys 397: 298-304, 2002.
23. Campbell B, Adams J, Shin YK, and Lefer AM. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 31: 467-476, 1999.
24. Cao PR, Kim HJ, and Lecker SH. Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37: 2088-2097, 2005.
25. Cardozo T and Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol 5: 739-751, 2004.
26. Carrard G, Bulteau AL, Petropoulos I, and Friguet B. Impairment of proteasome structure and function in aging. Int J Biochem Cell Biol 34: 1461-1474, 2002.
27. Castro A, Bernis C, Vigneron S, Labbe JC, and Lorca T. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 24: 314-325, 2005.
28. Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC, Bang ML, Trombitas K, Granzier H, Gregorio CC, Sorimachi H, and Labeit S. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 306: 717-726, 2001.
29. Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, Mitsui Y, and Magae J. Mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 9: 79-84, 1998.
30. Chen P and Hochstrasser M. Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly. Cell 86: 961-972, 1996.
31. Chen Q, Liu JB, Horak KM, Zheng H, Kumarapeli AR, Li J, Li F, Gerdes AM, Wawrousek EF, and Wang X. Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res 97: 1018-1026, 2005.
32. Chondrogianni N and Gonos ES. Proteasome dysfunction in mammalian aging: steps and factors involved. Exp Gerontol 40: 931-938, 2005.
33. Chondrogianni N, Tzavelas C, Pemberton AJ, Nezis IP, Rivett AJ, and Gonos ES. Overexpression of proteasome β5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates. J Biol Chem 280: 11840-11850, 2005.
34. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6: 79-87, 2005.
35. Ciechanover A and Ben Saadon R. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol 14: 103-106, 2004.
36. Ciechanover A, Orian A, and Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22: 442-451, 2000.
37. Ciechanover A, Hod Y, and Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 81: 1100-1105, 1978.
38. + channels. Physiol Rev 85: 33-47, 2005.
39. Conconi M, Szweda LI, Levine RL, Stadtman ER, and Friguet B. Age-related decline of rat liver multicatalytic proteinase activity and protection from oxidative inactivation by heat-shock protein 90. Arch Biochem Biophys 331: 232-240, 1996.
40. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J, and Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 3: 93-96, 2001.
41. Coux O, Nothwang HG, Silva P, I, Recillas TF, Bey F, and Scherrer K. Phylogenic relationships of the amino acid sequences of prosome (proteasome, MCP) subunits. Mol Gen Genet 245: 769-780, 1994.
42. Dantuma NP, Heessen S, Lindsten K, Jellne M, and Masucci MG. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci USA 97: 8381-8385, 2000.
43. Das S, Powell SR, Wang P, Divald A, Nesaretnam K, Tosaki A, Cordis GA, Maulik N, and Das DK. Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. Am J Physiol Heart Circ Physiol 289: H361-H367, 2005.
44. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83: 301-310, 2001.
45. Demand J, Luders J, and Hohfeld J. The carboxy-terminal domain of Hsc70 provides binding sites for a distinct set of chaperone cofactors. Mol Cell Biol 18: 2023-2028, 1998.
46. DeMartino GN. Purification of PA700, the 19S regulatory complex of the 26S proteasome. Methods Enzymol 398: 295-306, 2005.
47. Deruisseau KC, Kavazis AN, and Powers SK. Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp Gerontol 40: 526-531, 2005.
48. Deshaies RJ. SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15: 435-467, 1999.
49. Desterro JM, Rodriguez MS, and Hay RT. Regulation of transcription factors by protein degradation. Cell Mol Life Sci 57: 1207-1219, 2000.
50. + channels. Proc Natl Acad Sci USA 101: 11886-11890, 2004.
51. Divald A and Powell SR. Proteasome mediates removal of proteins oxidized during myocardial ischemia. Free Radic Biol Med 40: 156-164, 2006.
52. Dong X, Liu J, Zheng H, Glasford JW, Huang W, Chen QH, Harden NR, Li F, Gerdes AM, and Wang X. In situ dynamically monitoring the proteolytic function of the ubiquitin-proteasome system in cultured cardiac myocytes. Am J Physiol Heart Circ Physiol 287: H1417-H1425, 2004.
53. Dorn GW and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115: 527-537, 2005.
54. Driscoll J and Goldberg AL. Skeletal muscle proteasome can degrade proteins in an ATP-dependent process that does not require ubiquitin. Proc Natl Acad Sci USA 86: 787-791, 1989.
55. Dubiel W and Gordon C. Ubiquitin pathway: another link in the polyubiquitin chain? Curr Biol 9: R554-R557, 1999.
56. Elliott PJ, Zollner TM, and Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 81: 235-245, 2003.
57. Etlinger JD and Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci USA 74: 54-58, 1977.
58. Fagan JM, Waxman L, and Goldberg AL. Skeletal muscle and liver contain a soluble ATP + ubiquitin-dependent proteolytic system. Biochem J 243: 335-343, 1987.
59. Fang S and Weissman AM. A field guide to ubiquitylation. Cell Mol Life Sci 61: 1546-1561, 2004.
60. Feeney-Burns L, Hilderbrand ES, and Eldridge S. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. Invest Ophthalmol Vis Sci 25: 195-200, 1984.
61. Ferrington DA, Husom AD, and Thompson LV. Altered proteasome structure, function, and oxidation in aged muscle. FASEB J 19: 644-646, 2005.
62. Finley D, Tanaka K, Mann C, Feldmann H, Hochstrasser M, Vierstra R, Johnston S, Hampton R, Haber J, Mccusker J, Silver P, Frontali L, Thorsness P, Varshavsky A, Byers B, Madura K, Reed SI, Wolf D, Jentsch S, Sommer T, Baumeister W, Goldberg A, Fried V, Rubin DM, and Toh-e A. Unified nomenclature for subunits of the Saccharomyces cerevisiae proteasome regulatory particle. Trends Biochem Sci 23: 244-245, 1998.
63. Fischer D, Sun X, Gang G, Pritts T, and Hasselgren PO. The gene expression of ubiquitin ligase E3α is upregulated in skeletal muscle during sepsis in rats-potential role of glucocorticoids. Biochem Biophys Res Commun 267: 504-508, 2000.
64. Fotia AB, Ekberg J, Adams DJ, Cook DI, Poronnik P, and Kumar S. Regulation of neuronal voltage-gated sodium channels by the ubiquitin-protein ligases Nedd4 and Nedd4-2. J Biol Chem 279: 28930-28935, 2004.
65. Freemont PS. RING for destruction? Curr Biol 10: R84-R87, 2000.
66. French RJ and Zamponi GW. Voltage-gated sodium and calcium channels in nerve, muscle, and heart. IEEE Trans Nanobioscience 4: 58-69, 2005.
67. Friguet B and Szweda LI. Inhibition of the multicatalytic proteinase (proteasome) by 4-hydroxy-2-nonenal cross-linked protein. FEBS Lett 405: 21-25, 1997.
68. Fu H, Reis N, Lee Y, Glickman MH, and Vierstra RD. Subunit interaction maps for the regulatory particle of the 26S proteasome and the COP9 signalosome. EMBO J 20: 7096-7107, 2001.
69. Fuchs SY, Fried VA, and Ronai Z. Stress-activated kinases regulate protein stability. Oncogene 17: 1483-1490, 1998.
70. Fujita E, Mukasa T, Tsukahara T, Arahata K, Omura S, and Momoi T. Enhancement of CPP32-like activity in the TNF-treated U937 cells by the proteasome inhibitors. Biochem Biophys Res Commun 224: 74-79, 1996.
71. Gaczynska M and Osmulski PA. Small-molecule inhibitors of proteasome activity. Methods Mol Biol 301: 3-22, 2005.
72. Gaczynska M, Osmulski PA, Gao Y, Post MJ, and Simons M. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42: 8663-8670, 2003.
73. Gaczynska M, Rock KL, and Goldberg AL. Role of proteasomes in antigen presentation. Enzyme Protein 47: 354-369, 1993.
74. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, Li M, Sato K, Saluja AK, Steer ML, Goldberg AL, and Simons M. Inhibition of ubiquitin-proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide. J Clin Invest 106: 439-448, 2000.
75. George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest 115: 1990-1999, 2005.
76. Gerlinger UM, Guckel R, Hoffmann M, Wolf DH, and Hilt W. Yeast cycloheximide-resistant crl mutants are proteasome mutants defective in protein degradation. Mol Biol Cell 8: 2487-2499, 1997.
77. Glickman MH and Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428, 2002.
78. Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z, Baumeister W, Fried VA, and Finley D. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94: 615-623, 1998.
79. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003.
80. Goldberg AL, Cascio P, Saric T, and Rock KL. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39: 147-164, 2002.
81. Goldberg AL, Gaczynska M, Grant E, Michalek M, and Rock KL. Functions of the proteasome in antigen presentation. Cold Spring Harb Symp Quant Biol 60: 479-490, 1995.
82. Gomes AV, Zong C, Edmondson RD, Berhane BT, Wang GW, Le S, Young G, Zhang J, Vondriska TM, Whitelegge JP, Jones RC, Joshua IG, Thyparambil S, Pantaleon D, Qiao J, Loo J, and Ping P. The murine cardiac 26S proteasome: an organelle awaiting exploration. Ann NY Acad Sci 1047: 197-207, 2005.
83. Gomes MD, Lecker SH, Jagoe RT, Navon A, and Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98: 14440-14445, 2001.
84. Gorbea C, Taillandier D, and Rechsteiner M. Assembly of the regulatory complex of the 26S proteasome. Mol Biol Rep 26: 15-19, 1999.
85. Gotthardt M, Hammer RE, Hubner N, Monti J, Witt CC, McNabb M, Richardson JA, Granzier H, Labeit S, and Herz J. Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure. J Biol Chem 278: 6059-6065, 2003.
86. Grimm LM and Osborne BA. Apoptosis and the proteasome. Results Probl Cell Differ 23: 209-228, 1999.
87. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, and Finley D. A gated channel into the proteasome core particle. Nat Struct Biol 7: 1062-1067, 2000.
88. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, and Huber R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386: 463-471, 1997.
89. Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf DH, and Huber R. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA 96: 10976-10983, 1999.
90. Groll M and Huber R. Substrate access and processing by the 20S proteasome core particle. Int J Biochem Cell Biol 35: 606-616, 2003.
91. Groll M and Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695: 33-44, 2004.
92. Haglund K, Di Fiore PP, and Dikic I. Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 28: 598-603, 2003.
93. Harris KF, Shoji I, Cooper EM, Kumar S, Oda H, and Howley PM. Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc Natl Acad Sci USA 96: 13738-13743, 1999.
94. Hasselgren PO and Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 233: 9-17, 2001.
95. Hatakeyama S and Nakayama KI. U-box proteins as a new family of ubiquitin ligases. Biochem Biophys Res Commun 302: 635-645, 2003.
96. Hatakeyama S, Yada M, Matsumoto M, Ishida N, and Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 276: 33111-33120, 2001.
97. Hattori R, Otani H, Uchiyama T, Imamura H, Cui J, Maulik N, Cordis GA, Zhu L, and Das DK. Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning. Am J Physiol Heart Circ Physiol 281: H1066-H1074, 2001.
98. Heinemeyer W, Ramos PC, and Dohmen RJ. The ultimate nanoscale mincer: assembly, structure and active sites of the 20S proteasome core. Cell Mol Life Sci 61: 1562-1578, 2004.
99. Heink S, Ludwig D, Kloetzel PM, and Kruger E. IFN-γ-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci USA 102: 9241-9246, 2005.
100. Heling A, Zimmermann R, Kostin S, Maeno Y, Hein S, Devaux B, Bauer E, Klovekorn WP, Schlepper M, Schaper W, and Schaper J. Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium. Circ Res 86: 846-853, 2000.
101. Henderson CJ, Aleo E, Fontanini A, Maestro R, Paroni G, and Brancolini C. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 12: 1240-1254, 2005.
102. Herrmann J, Ciechanover A, Lerman LO, and Lerman A. The ubiquitin-proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res 61: 11-21, 2004.
103. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 9: 788-799, 1997.
104. Hicke L, Schubert HL, and Hill CP. Ubiquitin-binding domains. Nat Rev Mol Cell Biol 6: 610-621, 2005.
105. Higami Y and Shimokawa I. Apoptosis in the aging process. Cell Tissue Res 301: 125-132, 2000.
106. Hirano Y, Hendil KB, Yashiroda H, Iemura S, Nagane R, Hioki Y, Natsume T, Tanaka K, and Murata S. A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes. Nature 437: 1381-1385, 2005.
107. Hirsch C, Jarosch E, Sommer T, and Wolf DH. Endoplasmic reticulum-associated protein degradation - one model fits all? Biochim Biophys Acta 1695: 215-223, 2004.
108. Hoppe T. Multiubiquitylation by E4 enzymes: "one size" doesn't fit all. Trends Biochem Sci 30: 183-187, 2005.
109. Husom AD, Peters EA, Kolling EA, Fugere NA, Thompson LV, and Ferrington DA. Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 421: 67-76, 2004.
110. Ishii T, Sakurai T, Usami H, and Uchida K. Oxidative modification of proteasome: identification of an oxidation-sensitive subunit in 26 s proteasome. Biochemistry 44: 13893-13901, 2005.
111. Jana NR, Dikshit P, Goswami A, and Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 279: 11680-11685, 2004.
112. Jesenberger V and Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3: 112-121, 2002.
113. Kajstura J, Cheng W, Sarangarajan R, Li P, Li B, Nitahara JA, Chapnick S, Reiss K, Olivetti G, and Anversa P. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am J Physiol Heart Circ Physiol 271: H1215-H1228, 1996.
114. Kamikubo T and Hayashi T. Changes in proteasome activity following transient ischemia. Neurochem Int 28: 209-212, 1996.
115. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, and Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 101: 18135-18140, 2004.
116. Keller JN, Hanni KB, and Markesbery WR. Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech Ageing Dev 113: 61-70, 2000.
117. Keller JN, Huang FF, and Markesbery WR. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98: 149-156, 2000.
118. Kettelhut IC, Pepato MT, Migliorini RH, Medina R, and Goldberg AL. Regulation of different proteolytic pathways in skeletal muscle in fasting and diabetes mellitus. Braz J Med Biol Res 27: 981-993, 1994.
119. Keyvani K, Reinecke S, Abts HF, Paulus W, and Witte OW. Suppression of proteasome C2 contralateral to ischemic lesions in rat brain. Brain Res 858: 386-392, 2000.
120. Khan S, van den BM, Schwarz K, de Giuli R, Diener PA, and Groettrup M. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. J Immunol 167: 6859-6868, 2001.
121. Kingsbury DJ, Griffin TA, and Colbert RA. Novel propeptide function in 20S proteasome assembly influences β-subunit composition. J Biol Chem 275: 24156-24162, 2000.
122. Kirshenbaum LA. Bcl-2 intersects the NFκB signalling pathway and suppresses apoptosis in ventricular myocytes. Clin Invest Med 23: 322-330, 2000.
123. Kisselev AF and Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8: 739-758, 2001.
124. Kisselev AF and Goldberg AL. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol 398: 364-378, 2005.
125. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2: 179-187, 2001.
126. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, and Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96: 635-644, 1999.
127. Korthuis RJ, Gute DC, Blecha F, and Ross CR. PR-39, a proline/arginine-rich antimicrobial peptide, prevents postischemic microvascular dysfunction. Am J Physiol Heart Circ Physiol 277: H1007-H1013, 1999.
128. Kostin S, Pool L, Elsasser A, Hein S, Drexler HC, Arnon E, Hayakawa Y, Zimmermann R, Bauer E, Klovekorn WP, and Schaper J. Myocytes die by multiple mechanisms in failing human hearts. Circ Res 92: 715-724, 2003.
129. Krappmann D and Scheidereit C. A pervasive role of ubiquitin conjugation in activation and termination of IκB kinase pathways. EMBO Rep 6: 321-326, 2005.
130. Kroll M, Arenzana-Seisdedos F, Bachelerie F, Thomas D, Friguet B, and Conconi M. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol 6: 689-698, 1999.
131. Kuhn DJ, Burns AC, Kazi A, and Dou QP. Direct inhibition of the ubiquitin-proteasome pathway by ester bond-containing green tea polyphenols is associated with increased expression of sterol regulatory element-binding protein 2 and LDL receptor. Biochim Biophys Acta 1682: 1-10, 2004.
132. Kumarapeli AR, Horak KM, Glasford JW, Li J, Chen Q, Liu J, and Wang X. A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J 19: 2051-2063, 2005.
133. Lam YA, Lawson TG, Velayutham M, Zweier JL, and Pickart CM. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 416: 763-767, 2002.
134. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, and Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51, 2004.
135. Lecker SH, Solomon V, Price SR, Kwon YT, Mitch WE, and Goldberg AL. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest 104: 1411-1420, 1999.
136. Li D, Tapscoft T, Gonzalez O, Burch PE, Quinones MA, Zoghbi WA, Hill R, Bachinski LL, Mann DL, and Roberts R. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100: 461-464, 1999.
137. Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, and Patterson C. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 114: 1058-1071, 2004.
138. Li MX, Wang X, and Sykes BD. Structural based insights into the role of troponin in cardiac muscle pathophysiology. J Muscle Res Cell Motil 25: 559-579, 2004.
139. Lin KI, Baraban JM, and Ratan RR. Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ 5: 577-583, 1998.
140. Lindsten K, Menendez-Benito V, Masucci MG, and Dantuma NP. A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol 21: 897-902, 2003.
141. Liu J, Chen Q, Huang W, Horak KM, Zheng H, Mestril R, and Wang X. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J 20: 362-364, 2006.
142. Liu J, Tang M, Mestril R, and Wang X. Aberrant protein aggregation is essential for a mutant desmin to impair the proteolytic function of the ubiquitin-proteasome system in cardiomyocytes. J Mol Cell Cardiol 40: 451-454, 2006.
143. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, and Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 96: 11364-11369, 1999.
144. Louie J, Kapphahn R, and Ferrington D. Proteasome function and protein oxidation in the aged retina. Exp Eye Res 75: 271, 2002.
145. MacFarlane M, Merrison W, Bratton SB, and Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277: 36611-36616, 2002.
146. Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD, and Wu J. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 166: 3130-3142, 2001.
147. Marx J. Cell biology. SUMO wrestles its way to prominence in the cell. Science 307: 836-839, 2005.
148. McElhinny AS, Kakinuma K, Sorimachi H, Labeit S, and Gregorio CC. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 157: 125-136, 2002.
149. McElhinny AS, Perry CN, Witt CC, Labeit S, and Gregorio CC. Muscle-specific RING finger-2 (MURF-2) is important for microtubule, intermediate filament and sarcomeric M-line maintenance in striated muscle development. J Cell Sci 117: 3175-3188, 2004.
150. McNulty PH, Jagasia D, Cline GW, Ng CK, Whiting JM, Garg P, Shulman GI, and Soufer R. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation 101: 917-922, 2000.
151. Medina R, Wing SS, and Goldberg AL. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J 307: 631-637, 1995.
152. Medina R, Wing SS, Haas A, and Goldberg AL. Activation of the ubiquitin-ATP-dependent proteolytic system in skeletal muscle during fasting and denervation atrophy. Biomed Biochim Acta 50: 347-356, 1991.
153. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, and Kruger E. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 278: 21517-21525, 2003.
154. Menendez-Benito V, Verhoef LG, Masucci MG, and Dantuma NP. Endoplasmic reticulum stress compromises the ubiquitin-proteasome system. Hum Mol Genet 14: 2787-2799, 2005.
155. Mizushima N, Yoshimori T, and Ohsumi Y. Role of the Apg12 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 35: 553-561, 2003.
156. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, and Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215-228, 1998.
157. Moore DJ, Dawson VL, and Dawson TM. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. Neuromolecular Med 4: 95-108, 2003.
158. Mullapudi S, Pullan L, Bishop OT, Khalil H, Stoops JK, Beckmann R, Kloetzel PM, Kruger E, and Penczek PA. Rearrangement of the 16S precursor subunits is essential for the formation of the active 20S proteasome. Biophys J 87: 4098-4105, 2004.
159. Nakagawa T, Zhu H, Morishima N, Li E, Xu J, Yankner BA, and Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 403: 98-103, 2000.
160. Nandi D, Woodward E, Ginsburg DB, and Monaco JJ. Intermediates in the formation of mouse 20S proteasomes: implications for the assembly of precursor β-subunits. EMBO J 16: 5363-5375, 1997.
161. Nitahara JA, Cheng W, Liu Y, Li B, Leri A, Li P, Mogul D, Gambert SR, Kajstura J, and Anversa P. Intracellular calcium, DNase activity and myocyte apoptosis in aging Fischer 344 rats. J Mol Cell Cardiol 30: 519-535, 1998.
162. Nuber U and Scheffner M. Identification of determinants in E2 ubiquitin-conjugating enzymes required for hect E3 ubiquitin-protein ligase interaction. J Biol Chem 274: 7576-7582, 1999.
163. Oakley CE, Hambly BD, Curmi PM, and Brown LJ. Myosin binding protein C: structural abnormalities in familial hypertrophic cardiomyopathy. Cell Res 14: 95-110, 2004.
164. Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ, and Mook-Jung I. Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev 126: 1292-1299, 2005.
165. Okada K, Minamino T, Tsukamoto Y, Liao Y, Tsukamoto O, Takashima S, Hirata A, Fujita M, Nagamachi Y, Nakatani T, Yutani C, Ozawa K, Ogawa S, Tomoike H, Hori M, and Kitakaze M. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation 110: 705-712, 2004.
166. Okada K, Wangpoengtrakul C, Osawa T, Toyokuni S, Tanaka K, and Uchida K. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J Biol Chem 274: 23787-23793, 1999.
167. Oldfors A, Tajsharghi H, Darin N, and Lindberg C. Myopathies associated with myosin heavy chain mutations. Acta Myol 23: 90-96, 2004.
168. Orlowski M and Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383: 1-16, 2000.
169. Orlowski RA. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6: 303-313, 1999.
170. Osna NA, Haorah J, Krutik VM, and Donohue TM Jr. Peroxynitrite alters the catalytic activity of rodent liver proteasome in vitro and in vivo. Hepatology 40: 574-582, 2004.
171. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, and Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37: 449-471, 2004.
172. Petropoulos I, Conconi M, Wang X, Hoenel B, Bregegere F, Milner Y, and Friguet B. Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. J Gerontol A Biol Sci Med Sci 55: B220-B227, 2000.
173. Pickart CM and Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695: 55-72, 2004.
174. Powell SR, Gurzenda EM, Mantell LL, Teichberg S, and Maulik D. Association of increased ubiquinated proteins with cardiac apoptosis. Antioxid Redox Signal 2: 103-112, 2000.
175. Powell SR, Wang P, Divald A, Teichberg S, Haridas V, McCloskey TW, Davies KJA, and Katzeff HL. Aggregates of oxidized proteins (lipofuscins) induce apoptosis through proteasome inhibition and dysregulation of pro-apoptotic
176. Powell SR, Wang P, Katzeff HL, Shringarpure R, Teoh C, Khaliulin I, Das DK, Davies KJA, and Schwalb H. Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function. Essential role of the proteasome. Antioxid Redox Signal 7: 538-546, 2005.
177. Price SR. Increased transcription of ubiquitin-proteasome system components: molecular responses associated with muscle atrophy. Int J Biochem Cell Biol 35: 617-628, 2003.
178. Pye J, Ardeshirpour F, McCain A, Bellinger DA, Merricks E, Adams J, Elliott PJ, Pien C, Fischer TH, Baldwin AS Jr, and Nichols TC. Proteasome inhibition ablates activation of NF-κB in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284: H919-H926, 2003.
179. Ramos PC, Hockendorff J, Johnson ES, Varshavsky A, and Dohmen RJ. Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly. Cell 92: 489-499, 1998.
180. Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJ, and Grune T. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 335: 637-642, 1998.
181. Richardson PG. A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 5: 1321-1331, 2004.
182. Rose IA, Warms JV, and Hershko A. A high molecular weight protease in liver cytosol. J Biol Chem 254: 8135-8138, 1979.
183. Rotin D, Staub O, and Haguenauer-Tsapis R. Ubiquitination and endocytosis of plasma membrane proteins: role of Nedd4/Rsp5p family of ubiquitin-protein ligases. J Membr Biol 176: 1-17, 2000.
184. Rougier JS, van Bemmelen MX, Bruce MC, Jespersen T, Gavillet B, Apotheloz F, Cordonier S, Staub O, Rotin D, and Abriel H. Molecular determinants of voltage-gated sodium channel regulation by the Nedd4/Nedd4-like proteins. Am J Physiol Cell Physiol 288: C692-C701, 2005.
185. Rubin DM, Glickman MH, Larsen CN, Dhruvakumar S, and Finley D. Active site mutants in the six regulatory particle ATPases reveal multiple roles for ATP in the proteasome. EMBO J 17: 4909-4919, 1998.
186. Sacheck JM, Ohtsuka A, McLary SC, and Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 287: E591-E601, 2004.
187. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, and Robbins J. Desmin-related cardiomyopathy in transgenic mice: a cardiac amyloidosis. Proc Natl Acad Sci USA 101: 10132-10136, 2004.
188. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, and Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399-412, 2004.
189. Sarikas A, Carrier L, Schenke C, Doll D, Flavigny J, Lindenberg KS, Eschenhagen T, and Zolk O. Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. Cardiovasc Res 66: 33-44, 2005.
190. Satoh K, Sasajima H, Nyoumura KI, Yokosawa H, and Sawada H. Assembly of the 26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit. Biochemistry 40: 314-319, 2001.
191. Sawada H, Muto K, Fujimuro M, Akaishi T, Sawada MT, Yokosawa H, and Goldberg AL. Different ratios in 20 S proteasomes and regulatory subunit complexes in two isoforms of the 26S proteasome purified from rabbit skeletal muscle. FEBS Lett 335: 207-212, 1993.
192. Scheffner M, Nuber U, and Huibregtse JM. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373: 81-83, 1995.
193. Schmidtke G, Kraft R, Kostka S, Henklein P, Frommel C, Lowe J, Huber R, Kloetzel PM, and Schmidt M. Analysis of mammalian 20S proteasome biogenesis: the maturation of β-subunits is an ordered two-step mechanism involving autocatalysis. EMBO J 15: 6887-6898, 1996.
194. Schmidtke G, Schmidt M, and Kloetzel PM. Maturation of mammalian 20S proteasome: purification and characterization of 13S and 16S proteasome precursor complexes. J Mol Biol 268: 95-106, 1997.
195. Shang F, Gong X, Palmer HJ, Nowell TR Jr, and Taylor A. Agerelated decline in ubiquitin conjugation in response to oxidative stress in the lens. Exp Eye Res 64: 21-30, 1997.
196. Sitte N, Huber M, Grune T, Ladhoff A, Doecke WD, von Zglinicki T, and Davies KJ. Proteasome inhibition by lipofuscin/ceroid during post-mitotic aging of fibroblasts. FASEB J 14: 1490-1498, 2000.
197. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, and Walsh K. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 280: 20814-20823, 2005.
198. Sohal RS, Marzabadi MR, Galaris D, and Brunk UT. Effect of ambient oxygen concentration on lipofuscin accumulation in cultured rat heart myocytes-a novel in vitro model of lipofuscinogenesis. Free Radic Biol Med 6: 23-30, 1989.
199. Solomon V, Baracos V, Sarraf P, and Goldberg AL. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. Proc Natl Acad Sci USA 95: 12602-12607, 1998.
200. Solomon V and Goldberg AL. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 271: 26690-26697, 1996.
201. Solomon V, Lecker SH, and Goldberg AL. The N-end rule pathway catalyzes a major fraction of the protein degradation in skeletal muscle. J Biol Chem 273: 25216-25222, 1998.
202. Spencer JA, Eliazer S, Ilaria RL Jr, Richardson JA, and Olson EN. Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J Cell Biol 150: 771-784, 2000.
203. Spoerri PE, Glees P, and El Ghazzawi E. Accumulation of lipofuscin in the myocardium of senile guinea pigs: dissolution and removal of lipofuscin following dimethylaminoethyl p-chlorophenoxyacetate administration. An electron microscopic study. Mech Ageing Dev 3: 311-321, 1974.
204. Stangl K, Gunther C, Frank T, Lorenz M, Meiners S, Ropke T, Stelter L, Moobed M, Baumann G, Kloetzel PM, and Stangl V. Inhibition of the ubiquitin-proteasome pathway induces differential heat-shock protein response in cardiomyocytes and renders early cardiac protection. Biochem Biophys Res Commun 291: 542-549, 2002.
205. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, and Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403, 2004.
206. Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, and Cohen GM. Caspase activation inhibits proteasome function during apoptosis. Mol Cell 14: 81-93, 2004.
207. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, and Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281: 1690-1693, 1998.
208. Taegtmeyer H, King LM, and Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for pharmacotherapy. Am J Cardiol 82: 54K-60K, 1998.
209. Tawa NE Jr, Odessey R, and Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 100: 197-203, 1997.
210. Taylor RG, Tassy C, Briand M, Robert N, Briand Y, and Ouali A. Proteolytic activity of proteasome on myofibrillar structures. Mol Biol Rep 21: 71-73, 1995.
211. Terman A, Abrahamsson N, and Brunk UT. Ceroid/lipofuscin-loaded human fibroblasts show increased susceptibility to oxidative stress. Exp Gerontol 34: 755-770, 1999.
212. Terman A and Brunk UT. Lipofuscin: mechanisms of formation and increase with age. APMIS 106: 265-276, 1998.
213. Tidball JG. Mechanical signal transduction in skeletal muscle growth and adaptation. J Appl Physiol 98: 1900-1908, 2005.
214. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol 1: 159-168, 2003.
215. Torok M and Etkin LD. Two B or not two B? Overview of the rapidly expanding B-box family of proteins. Differentiation 67: 63-71, 2001.
216. Unno M, Mizushima T, Morimoto Y, Tomisugi Y, Tanaka K, Yasuoka N, and Tsukihara T. The structure of the mammalian 20S proteasome at 2.75 A resolution. Structure 10: 609-618, 2002.
217. van Bemmelen MX, Rougier JS, Gavillet B, Apotheloz F, Daidie D, Tateyama M, Rivolta I, Thomas MA, Kass RS, Staub O, and Abriel H. Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ Res 95: 284-291, 2004.
218. van Laar T, van der Eb AJ, and Terleth C. A role for Rad23 proteins in 26S proteasome-dependent protein degradation? Mutat Res 499: 53-61, 2002.
219. Vaux DL and Silke J. IAPs, RINGs and ubiquitylation. Nat Rev Mol Cell Biol 6: 287-297, 2005.
220. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A, Chateau D, Chapon F, Tome F, Dupret JM, Paulin D, and Fardeau M. A missense mutation in the αB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 20: 92-95, 1998.
221. Volker C and Lupas AN. Molecular evolution of proteasomes. Curr Top Microbiol Immunol 268: 1-22, 2002.
222. von Zglinicki T, Nilsson E, Docke WD, and Brunk UT. Lipofuscin accumulation and ageing of fibroblasts. Gerontology 41: 95-108, 1995.
223. Wang X, Osinska H, Dorn GW, Nieman M, Lorenz JN, Gerdes AM, Witt S, Kimball T, Gulick J, and Robbins J. Mouse model of desmin-related cardiomyopathy. Circulation 103: 2402-2407, 2001.
224. Weekes J, Morrison K, Mullen A, Wait R, Barton P, and Dunn MJ. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 3: 208-216, 2003.
225. Welchman RL, Gordon C, and Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 6: 599-609, 2005.
226. Wilkinson KD, Urban MK, and Haas AL. Ubiquitin is the ATPdependent proteolysis factor I of rabbit reticulocytes. J Biol Chem 255: 7529-7532, 1980.
227. Willems AR, Schwab M, and Tyers M. A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. Biochim Biophys Acta 1695: 133-170, 2004.
228. Wing SS. Deubiquitinating enzymes - the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol 35: 590-605, 2003.
229. Wing SS, Haas AL, and Goldberg AL. Increase in ubiquitin-protein conjugates concomitant with the increase in proteolysis in rat skeletal muscle during starvation and atrophy denervation. Biochem J 307: 639-645, 1995.
230. Winstanley EK and Pentreath VW. Lipofuscin accumulation and its prevention by vitamin E in nervous tissue: quantitative analysis using snail buccal ganglia as a simple model system. Mech Ageing Dev 29: 299-307, 1985.
231. Witt E, Zantopf D, Schmidt M, Kraft R, Kloetzel PM, and Kruger E. Characterisation of the newly identified human Ump1 homologue POMP and analysis of LMP7(β5i) incorporation into 20S proteasomes. J Mol Biol 301: 1-9, 2000.
232. Witt SH, Granzier H, Witt CC, and Labeit S. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination. J Mol Biol 350: 713-722, 2005.
233. Xu C, Bailly-Maitre B, and Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115: 2656-2664, 2005.
234. Yang Y and Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 17: 790-799, 2003.
235. Yen HC, Espiritu C, and Chang EC. Rpn5 is a conserved proteasome subunit and required for proper proteasome localization and assembly. J Biol Chem 278: 30669-30676, 2003.
236. Zhang C, Xu Z, He XR, Michael LH, and Patterson C. CHIP, a cochaperone/ubiquitin ligase that regulates protein quality control, is required for maximal cardioprotection after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 288: H2836-H2842, 2005.
237. Zhang HG, Wang J, Yang X, Hsu HC, and Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23: 2009-2015, 2004.
238. Zwickl P, Voges D, and Baumeister W. The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 354: 1501-1511, 1999.